Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AD/PD™ 2021, Including Lecanemab (BAN2401) Data
Eisai Alzheimer's Disease Pipeline Research to be Presented at Virtual AD/PD™ 2021, Including Lecanemab (BAN2401) Data - Oral presentations and posters highlighting Eisai's investigational novel therapies and immunoassay system being studied for Alzheimer's disease and its clinical symptoms - Preliminary analyses evaluating brain amyloid beta reduction with lecanemab to be featured in oral presentation - Virtual symposium: The Science Behind the Aβ Pathway in Alzheimer's Disease News provided by Share this article Share this article WOODCLIFF LAKE, N.J., March 5, 2021 /PRNewswire/ -- Eisa...
Source: prnewswire.com